Reply to 'Use of Convalescent Plasma in the Treatment of COVID-19'
Overview
Overview
Authors
Authors
Affiliations
Affiliations
Soon will be listed here.
References
1.
Murakami N, Hayden R, Hills T, Al-Samkari H, Casey J, Del Sorbo L
. Therapeutic advances in COVID-19. Nat Rev Nephrol. 2022; 19(1):38-52.
PMC: 9574806.
DOI: 10.1038/s41581-022-00642-4.
View
2.
Bhimraj A, Morgan R, Shumaker A, Lavergne V, Baden L, Cheng V
. Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with COVID-19. Clin Infect Dis. 2020; .
PMC: 7197612.
DOI: 10.1093/cid/ciaa478.
View
3.
Ader F, Bauer J
. What progress has been made in treatment of immunocompromised COVID-19 patients?. Infect Dis Now. 2022; 52(8S):S12-S15.
PMC: 9468055.
DOI: 10.1016/j.idnow.2022.09.009.
View
4.
Estcourt L, Cohn C, Pagano M, Iannizzi C, Kreuzberger N, Skoetz N
. Clinical Practice Guidelines From the Association for the Advancement of Blood and Biotherapies (AABB): COVID-19 Convalescent Plasma. Ann Intern Med. 2022; 175(9):1310-1321.
PMC: 9450870.
DOI: 10.7326/M22-1079.
View
5.
Thompson M, Henderson J, Shah P, Rubinstein S, Joyner M, Choueiri T
. Association of Convalescent Plasma Therapy With Survival in Patients With Hematologic Cancers and COVID-19. JAMA Oncol. 2021; .
PMC: 8377563.
DOI: 10.1001/jamaoncol.2021.1799.
View